Q-Line Biotech Limited was originally incorporated in November 2010 as “POCT Services Private Limited” and transitioned to its current name and public status in March 2025. Based in Lucknow, the company is a significant player in the In-Vitro Diagnostic (IVD) industry, specializing in the manufacturing, trading, and distribution of biochemistry reagents, medical instruments, and consumables. Its core segments include Clinical Chemistry, Haematology, Immunodiagnostics, and Molecular Diagnostics. The company follows a B2B business model, supplying products to diagnostic service providers, hospitals, medical colleges, and distributors. As of December 2025, it maintains a widespread distribution network with 283 distributors across 25 states and union territories in India. The company has established strong brand recognition over 12 years, supported by in-house R&D and technology transfer agreements (TTAs) with global diagnostic companies. Currently, Q-Line operates four manufacturing facilities—three in Uttar Pradesh and one in Delhi. In February 2026, the company commissioned its fourth manufacturing unit dedicated to reagents, which significantly boosted its annual installed capacity for clinical chemistry reagents and Rapid/Elisa kits. The company's production processes are certified under ISO 13485:2016 and ISO 9001:2015, ensuring high standards of quality control and consistent product delivery. Looking toward the future, the company is implementing an expansion plan centered on scaling its manufacturing capabilities and strengthening its financial position. The IPO proceeds are primarily earmarked for working capital to support an increasing order book and the repayment of high-cost borrowings. By shifting from a trading-led to a manufacturing-intensive model, the company aims to enhance its margins and increase its market penetration both domestically and in international markets. As per financial performance, Q-Line Biotech Limited has posted total income / net profits of Rs 184.81 / 32.10 Cr (FY23), Rs 206.45 / Rs 34.45 Cr (FY24), Rs 322.58 Cr / 28.13 Cr (FY25) and Rs 236.50 Cr / 38.69 Cr (Upto Q3 FY26). So as per previous financials data, company has shown good growth, but trade receivables to total sales ratio is around 26% and 57% for FY25 and 9M FY26 and operating cash flow is negative in FY24, FY25 and 9M FY26. Company has an average EPS of Rs 25 and average RoNW of 23.17% for last three fiscals. Issue is priced at a P/BV of 2.44 as per NAV of Rs 140.81/- as on 31.12.25 If we attribute latest earnings of FY24, FY25 and annualised FY26 on equity post issue, then asking price is at a P/E of around 23.23, 28.44 and 15.51 respectively. As per RHP, there are no listed peers in the Indian market. On BRLM's front, Hem Securities Limited and Share India Capital Services Private Limited is associated with this IPOs and has handled 64 IPOs in last three fiscal years. From last 10 IPOs, 2 opened below issue price and remaining all opened above issue price or at par, on the day of listing. As of now, from last 10 IPOs, three are trading below issue price and remaining all are trading above issue price or at par. (as on 18.05.26) As per financials, Q-Line Biotech Limited has shown good growth, RoNW is 23.74% and P/E is 23.23, 28.44 and 15.51 respectively as per FY24, FY25 and annualised FY26 earnings. So, issue looks fully priced. But higher trade receivables and negative operating cash flow raise doubts. The company is a significant player in the In-Vitro Diagnostic (IVD) industry, specializing in the manufacturing, trading, and distribution of biochemistry reagents, medical instruments, and consumables. Performance of BRLM is good. So, we give NEUTRAL rating for this IPO. Readers must consult a qualified financial advisor prior to making any actual investment decisions.
✍️ Post a Comment